FIELD: cancer immunotherapy.
SUBSTANCE: isolated, ex vivo grown population of human T cells, a method for its production and pharmaceutical compositions based on it. An isolated, ex vivo grown human T cell population expresses a T cell receptor (TCR) specific HLA peptide complex containing the protein encoded by the HLA-C03:03 or HLA-C03:04 allele and the GAVGVGKSA mutant peptide; or a protein encoded by the HLA-C01:02 allele and a mutant AVGVGKSAL peptide. A method for producing a population of T cells involves priming a population of T cells with antigen presenting cells (APCs) containing a mutant RAS peptide or a polynucleotide encoding a polypeptide containing a mutant RAS peptide. RAS-specific T cells recognize mutated cells and activate the cytotoxic mechanism.
EFFECT: T cell population is suitable for the preparation of a composition for immunotherapy of cancer characterized by a RAS mutation.
15 cl, 6 dwg, 12 ex, 14 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND TREATMENT | 2020 |
|
RU2806915C2 |
| ANTIBODIES SPECIFIC FOR CD70 AND THEIR USE | 2019 |
|
RU2801093C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
| T-CELL RECEPTOR CONSTRUCTS AND THEIR USE | 2019 |
|
RU2785954C2 |
| CONJUGATES OF ANTIBODY TO CCR7 AND DRUG | 2018 |
|
RU2777662C2 |
